Sandra Calvin's most recent trade in Travere Therapeutics Inc was a trade of 7,402 Common Stock done at an average price of $40 . Disclosure was reported to the exchange on Dec. 24, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 24 Dec 2025 | 7,402 | 38,233 (0%) | 0% | 40 | 296,080 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 36.00 per share. | 15 Dec 2025 | 2,910 | 45,635 (0%) | 0% | 36 | 104,760 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 36.00 per share. | 04 Nov 2025 | 67,115 | 48,545 (0%) | 0% | 36 | 2,416,140 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2025 | 17,500 | 0 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.88 per share. | 04 Nov 2025 | 17,500 | 81,910 (0%) | 0% | 26.9 | 470,400 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2025 | 15,000 | 2,500 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.50 per share. | 04 Nov 2025 | 15,000 | 96,910 (0%) | 0% | 27.5 | 412,500 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2025 | 12,500 | 7,500 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.40 per share. | 04 Nov 2025 | 12,500 | 109,410 (0%) | 0% | 22.4 | 280,000 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.25 per share. | 04 Nov 2025 | 10,000 | 64,410 (0%) | 0% | 25.3 | 252,500 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2025 | 10,000 | 0 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2025 | 6,250 | 18,750 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.93 per share. | 04 Nov 2025 | 6,250 | 115,660 (0%) | 0% | 8.9 | 55,813 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2025 | 15,000 | 0 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 11 Feb 2025 | 15,000 | 63,654 (0%) | 0% | 25 | 375,000 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.46 per share. | 11 Feb 2025 | 15,000 | 78,654 (0%) | 0% | 15.5 | 231,900 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.23 per share. | 11 Feb 2025 | 10,000 | 73,654 (0%) | 0% | 16.2 | 162,300 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2025 | 10,000 | 0 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2025 | 10,000 | 0 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2025 | 10,000 | 0 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 11 Feb 2025 | 10,000 | 63,654 (0%) | 0% | 25 | 250,000 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.96 per share. | 11 Feb 2025 | 10,000 | 73,654 (0%) | 0% | 18.0 | 179,600 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 11 Feb 2025 | 10,000 | 63,654 (0%) | 0% | 25 | 250,000 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.44 per share. | 11 Feb 2025 | 10,000 | 73,654 (0%) | 0% | 17.4 | 174,400 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 11 Feb 2025 | 10,000 | 63,654 (0%) | 0% | 25 | 250,000 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 11 Feb 2025 | 9,244 | 54,410 (0%) | 0% | 25 | 231,100 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 26,000 | 26,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 13,000 | 67,002 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 20.12 per share. | 31 Jan 2025 | 3,348 | 63,654 (0%) | 0% | 20.1 | 67,362 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 18.94 per share. | 22 Jan 2025 | 925 | 54,002 (0%) | 0% | 18.9 | 17,520 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Dec 2024 | 15,000 | 0 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 17.22 per share. | 26 Dec 2024 | 15,000 | 54,927 (0%) | 0% | 17.2 | 258,278 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.67 per share. | 26 Dec 2024 | 15,000 | 69,927 (0%) | 0% | 12.7 | 190,050 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.67 per share. | 25 Nov 2024 | 15,000 | 67,017 (0%) | 0% | 12.7 | 190,050 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2024 | 15,000 | 15,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 18.30 per share. | 25 Nov 2024 | 12,090 | 54,927 (0%) | 0% | 18.3 | 221,258 | Common Stock |
| Travere Therapeutics Inc | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 25,000 | 25,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 12,500 | 53,837 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 8.53 per share. | 31 Jan 2024 | 2,820 | 52,017 (0%) | 0% | 8.5 | 24,058 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 1,000 | 54,837 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 9.07 per share. | 23 Jan 2024 | 910 | 41,337 (0%) | 0% | 9.1 | 8,252 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 16.59 per share. | 10 May 2023 | 436 | 42,369 (0%) | 0% | 16.6 | 7,233 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 16.12 per share. | 10 May 2023 | 122 | 42,247 (0%) | 0% | 16.1 | 1,967 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 20,000 | 20,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Sandra Calvin | SVP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 10,000 | 44,836 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Sandra Calvin | SVP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 21.75 per share. | 31 Jan 2023 | 1,671 | 43,165 (0%) | 0% | 21.8 | 36,348 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 22.42 per share. | 31 Jan 2023 | 360 | 42,805 (0%) | 0% | 22.4 | 8,071 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 21.90 per share. | 24 Jan 2023 | 905 | 35,028 (0%) | 0% | 21.9 | 19,823 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 21.63 per share. | 24 Jan 2023 | 192 | 34,836 (0%) | 0% | 21.6 | 4,153 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 28.00 per share. | 13 Sep 2022 | 349 | 35,933 (0%) | 0% | 28 | 9,772 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 21.92 per share. | 10 May 2022 | 445 | 35,733 (0%) | 0% | 21.9 | 9,756 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | SVP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 21.51 per share. | 10 May 2022 | 436 | 36,178 (0%) | 0% | 21.5 | 9,378 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | VP, Corp Controller and CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 17,500 | 17,500 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Sandra Calvin | VP, Corp Controller and CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 8,750 | 37,412 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Sandra Calvin | VP, Corp Controller and CAO | Sale of securities on an exchange or to another person at price $ 26.51 per share. | 31 Jan 2022 | 798 | 36,614 (0%) | 0% | 26.5 | 21,152 | Common Stock |
| Travere Therapeutics Inc | Sandra Calvin | VP, Corp Controller and CAO | Sale of securities on an exchange or to another person at price $ 24.58 per share. | 24 Jan 2022 | 934 | 28,662 (0%) | 0% | 24.6 | 22,955 | Common Stock |